End-of-day quote
Korea S.E.
18:00:00 2024-05-16 EDT
|
5-day change
|
1st Jan Change
|
3,765
KRW
|
0.00%
|
|
-0.79%
|
-15.77%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
262,935
|
394,737
|
477,802
|
114,342
|
60,805
|
Enterprise Value (EV)
1 |
236,542
|
382,720
|
473,510
|
107,584
|
57,387
|
P/E ratio
|
-103
x
|
-95.1
x
|
-36.5
x
|
-5
x
|
-4.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
525,581,679
x
|
238,211,476
x
|
-
|
EV / Revenue
|
-
|
-
|
520,860,841
x
|
224,134,002
x
|
-
|
EV / EBITDA
|
-69.1
x
|
-79.8
x
|
-44.2
x
|
-8.74
x
|
-6.02
x
|
EV / FCF
|
-40.1
x
|
-25.8
x
|
-57.4
x
|
-30.9
x
|
-2.89
x
|
FCF Yield
|
-2.49%
|
-3.88%
|
-1.74%
|
-3.24%
|
-34.6%
|
Price to Book
|
5.12
x
|
8.35
x
|
12.3
x
|
5.1
x
|
1.5
x
|
Nbr of stocks (in thousands)
|
9,579
|
9,699
|
9,731
|
9,731
|
13,603
|
Reference price
2 |
27,450
|
40,700
|
49,100
|
11,750
|
4,470
|
Announcement Date
|
20-02-29
|
21-03-01
|
22-03-01
|
23-03-01
|
24-02-29
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
909.1
|
480
|
-
|
EBITDA
1 |
-2,298
|
-3,421
|
-4,795
|
-10,723
|
-12,311
|
-9,534
|
EBIT
1 |
-2,375
|
-3,531
|
-5,287
|
-13,011
|
-14,911
|
-12,198
|
Operating Margin
|
-
|
-
|
-
|
-1,431.2%
|
-3,106.53%
|
-
|
Earnings before Tax (EBT)
1 |
-11,286
|
-2,494
|
-4,126
|
-13,071
|
-22,865
|
-11,611
|
Net income
1 |
-11,286
|
-2,494
|
-4,126
|
-13,071
|
-22,865
|
-11,611
|
Net margin
|
-
|
-
|
-
|
-1,437.76%
|
-4,763.45%
|
-
|
EPS
2 |
-1,424
|
-265.7
|
-427.9
|
-1,346
|
-2,350
|
-1,078
|
Free Cash Flow
1 |
-11,116
|
-5,893
|
-14,832
|
-8,255
|
-3,485
|
-19,854
|
FCF margin
|
-
|
-
|
-
|
-908.07%
|
-726.13%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-01
|
20-02-29
|
21-03-01
|
22-03-01
|
23-03-01
|
24-02-29
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7,885
|
26,394
|
12,017
|
4,292
|
6,757
|
3,418
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11,116
|
-5,893
|
-14,832
|
-8,255
|
-3,485
|
-19,854
|
ROE (net income / shareholders' equity)
|
-283%
|
-7.69%
|
-8.37%
|
-30.4%
|
-74.7%
|
-36.9%
|
ROA (Net income/ Total Assets)
|
-15.5%
|
-6.61%
|
-6.48%
|
-15.1%
|
-17.9%
|
-13.9%
|
Assets
1 |
72,923
|
37,703
|
63,634
|
86,520
|
127,716
|
83,601
|
Book Value Per Share
2 |
1,574
|
5,359
|
4,877
|
3,983
|
2,306
|
2,977
|
Cash Flow per Share
2 |
103.0
|
175.0
|
358.0
|
535.0
|
848.0
|
984.0
|
Capex
1 |
5,817
|
4,284
|
11,715
|
3,112
|
1,203
|
6,922
|
Capex / Sales
|
-
|
-
|
-
|
342.29%
|
250.61%
|
-
|
Announcement Date
|
19-03-01
|
20-02-29
|
21-03-01
|
22-03-01
|
23-03-01
|
24-02-29
|
|
1st Jan change
|
Capi.
|
---|
| -15.77% | 37.85M | | +9.42% | 115B | | +11.84% | 106B | | -14.15% | 21.84B | | -1.05% | 21.96B | | -5.29% | 19.21B | | -38.29% | 17.71B | | -4.16% | 18.08B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|